COMVAX is indicated for vaccination against invasive disease caused by Haemophilus influenzae type b and against infection caused by all known subtypes of hepatitis B virus in infants 6 weeks to 15 months of age born to HBsAg-negative mothers. COMVAX should be administered at 2, 4, and 12 to 15 months of age. COMVAX should not be administered to any infant before the age of 6 weeks.

Select Safety Information

COMVAX is contraindicated in patients with hypersensitivity to yeast or any component of the vaccine. Patients who develop symptoms suggestive of hypersensitivity after an injection should not receive further injections of the vaccine.

As with other vaccines, COMVAX may not induce protective antibody levels immediately following vaccination and may not result in a protective antibody response in all individuals given the vaccine.

In clinical trials, the most common nonserious adverse experiences observed in >1% of children receiving COMVAX included injection-site reactions, somnolence, irritability, crying, and fever (>101°F); for a listing of adverse reactions, please read the Prescribing Information.

Before administering COMVAX, please read the Prescribing Information.

COMVAX is a registered trademark of Merck & Co., Inc.